Allodynic Therapeutics, Inc
7
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
28.6%
2 terminated/withdrawn out of 7 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial
Role: lead
The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination
Role: lead
An Acute Migraine Factorial Study
Role: lead
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
Role: lead
Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4)
Role: lead
Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine
Role: lead
Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain
Role: lead
All 7 trials loaded